Fresenius SE & Co. KGaA · XETR:FRE

Fresenius SE & Co. KGaA — Non-Deal Roadshow (May 2023)

38 slides from Fresenius SE & Co. KGaA's roadshow presentation, May 10, 2023

  1. Slide 1: Executing on #FutureFresenius: Strong Q1/23 for Operating Companies

    Executing on #FutureFresenius: Strong Q1/23 for Operating Companies, structural simplification on track London, May 10, 2023

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive

  3. Slide 3: Business update

    1 Business update 2 Financial review Q1/23 3 #FutureFresenius

  4. Slide 4: #FutureFresenius – steady momentum

    #FutureFresenius moving forward: Strong Q1 for Operating Companies, simplification on track  Kabi and Helios accelerating performance with strong Q1 Structural productivity savings ramping up and showing impact Enhanced transparency on Kabi; CMD May 25 FMC deconsolidation moving ahead rapidly; EGM

  5. Slide 5: Q1/23 – Good momentum at Kabi and Helios; outlook confirmed

    Q1/23 – Good momentum at Kabi and Helios; earnings hit by Investment Companies; outlook confirmed  Good growth momentum in all segments  Revenues €10.2 bn (+5%)  Operating Companies at upper end of growth band  Operating Companies EBIT broadly flat, Investment Companies EBIT dilutive  EBIT incl

  6. Slide 6: Strong Q1/23 for Operating Companies – Kabi and Helios delivering

    Strong Q1/23 for Operating Companies – Kabi and Helios delivering 14 17 9 11 EBIT (MARGIN) €289m 14.5% €311m 10.1% REVENUE €2.0bn +7% €3.1bn +5% (ORG. GROWTH) 4 7 3 5 KEY  Strong organic revenue growth paced  Healthy organic revenue growth driven MESSAGES by all three growth vectors Nutrition, by

  7. Slide 7: FMC turnaround taking shape; EGM July 14

    FMC turnaround taking shape; EGM July 14  Structural simplification on track  EGM vote July 14  Enhanced reporting transparency  Improving treatment volumes  Focus on margin improvements  FME25 starting to gain traction All growth rates in constant currency (cc) Before special items Roadshow L

  8. Slide 8: Advancing patient care with innovative strengths in products and services

    Advancing patient care with innovative strengths in products and services Recent highlights (sample) Vizient Innovative Technology Contract Pilot project for filtration concept and awarded for the Ivenix Infusion System reprocessing of narcotic gases FDA US agreed to waive KabiClear Line 2 in PU App

  9. Slide 9: Financial review Q1/23

    1 Business update 2 Financial review Q1/23 3 #FutureFresenius

  10. Slide 10: Q1/23 – Good growth momentum

    Q1/23 – Good growth momentum €10.2bn €908m €554m  Healthy revenue growth of 5% in constant currency +5% -11/-10%1 -7%  EBIT decline driven by expected annualization of inflationary effects such as cost increases for personnel, material, logistics, and energy REVENUE EBIT EBIT (INCL. FMC) (EX FMC)

  11. Slide 11: Fresenius Kabi off to a good start to the year

    Fresenius Kabi off to a good start to the year Q1/23 results QUARTERLY FINANCIALS MAIN DEVELOPMENTS  Strong organic revenue growth in 15.9% all three growth vectors; 14.5% 2,000 EBIT Margin Biopharmaceuticals with ongoing strong growth momentum 14.3% 11.6% 13.5%  Healthy growth in IV drugs & Reven

  12. Slide 12: Fresenius Helios delivers solid Q1/23

    Fresenius Helios delivers solid Q1/23 Q1/23 results QUARTERLY FINANCIALS MAIN DEVELOPMENTS 3,500  Healthy organic revenue growth 10.4% 10.4% 11.7% 10.1% mainly driven by Helios Spain including Latin America and Fertility EBIT Margin 3,000  EBIT margin well within structural margin band – 7.8% cont

  13. Slide 13: Fresenius Vamed: Weak quarter, fixing underway

    Fresenius Vamed: Weak quarter, fixing underway Q1/23 results QUARTERLY FINANCIALS MAIN DEVELOPMENTS 900 1.7% 2.0%  Revenue growth driven by Technical 1.6% Services business and European Project business Revenue €m  Weak EBIT negatively impacted by 500 -1.3% legacy project portfolio, business initi

  14. Slide 14: Illustrative financial implications from change of FMC's legal form

    Illustrative financial implications from change of Fresenius Medical Care’s legal form Incl. FMC Excl. FMC Current 2023 €m Q1/23 Q1/23 FMC fully consolidated Revenue 10,225 5,546 EGM July 14 EBIT 908 554 IFRS 5 application starts, likely leading to one-time non-cash P&L effect (special item); as per

  15. Slide 15: Operating cash flow increased in Q1/23

    Operating cash flow increased in Q1/23 Q1/23 Q1/22 €m Q1/23 Q1/22  Q1 structurally a weaker CF LTM LTM quarter with catch-up effects OCF 175 101 4,272 4,527 over the course of the year % OCF Margin 1.7% 1.0% 10.3% 11.8%  Q1 OCF increased by 73% over weak prior year quarter Capex -352 -356 -1,773 -

  16. Slide 16: Capital efficiency and returns to be improved over next quarters

    Capital efficiency and returns to be improved over next quarters ROIC CCR NET DEBT/EBITDA1 10% 1.4 1.3 4.0 x 3.79 9% 1.2 1.1 1.1 3.65 3.61 8% 3.51 1.0 2 1.1 3.5 x 3.44 6.7 6.5 7% 5.9 0.8 0.7 6% 5.1 4.8 0.6 5% 3.0 x 4% 0.4 Q1/22: 5.6 LTM Q1/22: 1.0 Q1/22: 3.59 3% 0.2 2% 0.0 2.5 x 2019 2020 2021 2022

  17. Slide 17: Ambitious cost savings program announced – execution well on track

    Ambitious cost savings program announced – execution well on track Planned until 2025 Focus on 2023 Cost savings program is fully on Cost savings – EBIT view Expected Delivered track to deliver on 2023 targets Thereof FME ~€1,000m 2023 in Q1 and beyond ~€650m ~ €450m EBIT savings achieved – €500m 

  18. Slide 18: #FutureFresenius

    1 Business update 2 Financial review Q1/23 3 #FutureFresenius

  19. Slide 19: #FutureFresenius – Busy months, more to come

    #FutureFresenius – Busy months, more to come Deliver 2023 and upgrade performance 2024+ Complete FMC deconsolidation  Preparations fully on track  Extraordinary General Meeting July 14 Kabi: Intensify focus and transparency  Business-oriented disclosure available  Upcoming CMD May 25 Continuousl

  20. Slide 20: FMC deconsolidation on track for completion in Q3-4 2023

    FMC deconsolidation on track for completion in Q3-4 2023 2023 Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Q1 Call Announcement Change of Legal Form Selection Procedure for  New FMC Supervisory Board Legal Documentation Change of Invitation to FMC EGM legal form 14 July: FMC EGM Contestation Period

  21. Slide 21: Fresenius Kabi Capital Market Day coming up in May

    Fresenius Kabi Capital Market Day coming up in May Key topics London, UK  #FutureFresenius – Fresenius Kabi’s contributions as operating company in advancing patient care May 25, 2023  Vision 2026 – Driving for margin enhancement and transformative growth  “3+1” strategy delivery  Performance ma

  22. Slide 22: Attachments

    = FRESENIUS Attachments

  23. Slide 23: Outlook for FY/23

    Outlook for FY/23 Fresenius Group Revenue growth (organic) EBIT (cc growth)1 including FMC: EBIT (cc growth) excluding FMC: Low-to-mid-single-digit growth Broadly flat-to-high-single Broadly flat-to-mid-single digit decline digit decline Operating Companies Investment Companies  Low-to-mid-single-d

  24. Slide 24: FY/23 – Other financial KPIs

    FY/23 – Other financial KPIs One cent change in EUR/USD implies an annual effect of ~€140m on revenue, ~€15m on EBIT and Foreign exchange ~€4m on net income Higher interest rates leading to increased interest expenses of €700 to €750m for the group Profitability Interest expense depending on refinan

  25. Slide 25: Illustrative financial implications from change of FMC's legal form

    Illustrative financial implications from change of Fresenius Medical Care’s legal form 2023 July 14 Registration in H2/23 After conversion Current Extraordinary General Meeting Registration in commercial register At equity accounting • FMC fully • Application of IFRS 5 • Effective date AG conversion

  26. Slide 26: Fresenius Kabi: Q1/23 Organic Revenue Growth by Product Group

    Fresenius Kabi: Q1/23 Organic Revenue Growth by Product Group Δ YoY €m Q1/23 organic MedTech 378 9% Nutrition 602 8% Biopharma 71 57% Growth Vectors1 1,051 10% Pharma 940 3% (IV Drugs & Fluids) Total revenue 1,991 7% 1 consists of MedTech, Nutrition, Biopharma Roadshow London, May 10, 2023 © Freseni

  27. Slide 27: Fresenius Kabi: Q1/23 EBIT(DA) development

    Fresenius Kabi: Q1/23 EBIT(DA) development €m Q1/23 Δ YoY cc Total EBITDA 403 0% Margin 20.2% -120 bps Growth Vectors1 96 -17% Margin 9.2% -270 bps Pharma (IV Drugs & Fluids) 197 4% Margin 21.0% +60 bps Corporate -4 37% Total EBIT 289 -4% Margin 14.5% -140 bps All figures before special items Margin

  28. Slide 28: Fresenius Helios: Q1/23 Key Financials

    Fresenius Helios: Q1/23 Key Financials €m Q1/23 Δ YoY cc Total revenue 3,066 5%1 Thereof Helios Germany 1,828 3%1 Thereof Helios Spain 1,170 8%1 Thereof Helios Fertility 66 18%1 Total EBIT 311 2% Margin 10.1% -30 bps Thereof Helios Germany 155 1% Margin 8.5% -10 bps Thereof Helios Spain 157 4% Margi

  29. Slide 29: Fresenius Helios: Key Metrics

    Fresenius Helios: Key Metrics Q1/23 FY/22 Δ Helios Germany Hospitals 87 87 0% - Acute care hospitals 84 84 0% Beds 30,165 30,352 -1% - Acute care hospitals 29,599 29,786 -1% Admissions 1,433,728 5,508,158 - patients treated in hospital 287,317 1,079,776 - patients treated as outpatient 1,146,411 4,4

  30. Slide 30: Fresenius Vamed: Q1/23 Key Financials

    Fresenius Vamed: Q1/23 Key Financials €m Q1/23 Δ YoY cc Total revenue 583 13% Thereof organic revenue 13% Project business 147 36% Service business 436 7% Total EBIT1 -27 -- Order intake2 43 -- Order backlog2 3,580 -3%3 1 Before special items 2 Project business only 3 Versus December 31, 2022 Roadsh

  31. Slide 31: Fresenius Group: Calculation of Noncontrolling Interests

    Fresenius Group: Calculation of Noncontrolling Interests €m Q1/23 Q1/22 Earnings before tax and noncontrolling interests 738 881 Taxes -184 -200 Noncontrolling interests, thereof -165 -218 Fresenius Medical Care net income not attributable to Fresenius -106 -137 (FY/22: ~68%) Noncontrolling interest

  32. Slide 32: Fresenius Group: Cash Flow

    Fresenius Group: Cash Flow €m Q1/23 Q1/23 LTM Δ YoY LTM Margin Operating Cash Flow 175 4,272 10.3% 73% Capex (net) -352 -1,773 -4.3% 1% Free Cash Flow -177 2,499 6.0% 31% (before acquisitions and dividends) Acquisitions (net) -51 -789 Dividends -53 -887 Free Cash Flow -281 823 2.0% 30% (after acquis

  33. Slide 33: Reconciliation adjusted Free Cash Flow for CCR

    Fresenius Group: Reconciliation adjusted Free Cash Flow for CCR €m Q1/23 Q1/22 Operating Cash Flow 175 101 Capex (net) -352 -356 Free Cash Flow -177 -255 (before acquisitions and dividends) Special items (net income before minorities) +91 +82 Interests +170 +119 (before special items) Taxes +184 +20

  34. Slide 34: Cash Flow development Q1/23

    Cash Flow development Q1/23 Operating Cash Flow Capex (net) Free Cash Flow1 €m Q1/23 Q1/22 Q1/23 Q1/22 Q1/23 Q1/22 Q1/23 Q1/22 Q1/23 Q1/22 Q1/23 Q1/22 Margin Margin Margin Margin Margin Margin 21 133 1.1% 7.2% -83 -94 -4.2% -5.1% -62 39 -3.1% 2.1% 108 -136 3.5% -4.6% -95 -91 -3.1% -3.1% 13 -227 0.4%

  35. Slide 35: Cash Flow development Q1/23 LTM

    Cash Flow development Q1/23 LTM Operating Cash Flow Capex (net) Free Cash Flow1 €m Q1/23 Q1/22 Q1/23 Q1/22 Q1/23 Q1/22 Q1/23 Q1/22 Q1/23 Q1/22 Q1/23 Q1/22 LTM LTM Margin Margin LTM LTM Margin Margin LTM LTM Margin Margin 729 1,058 9.1% 14.5% -507 -506 -6.3% -6.9% 222 552 2.8% 7.6% 1,611 853 13.6% 7.

  36. Slide 36: Revenue by Business Segment – FX, Acquisitions/Divestitures Effects Q1/23

    Revenue by Business Segment – FX, Acquisitions/Divestitures Effects Q1/23 Growth at Currency Growth at Divesti- actual translation constant Organic Acquisi- tures/ €m Q1/23 Q1/22 rates effects rates growth tions Others Fresenius Kabi 1,991 1,847 8% 0% 8% 7% 2% -1% Fresenius Helios 3,066 2,931 5% 0%

  37. Slide 37: Financial Calendar / Contact

    Financial Calendar / Contact Financial Calendar Social Media 09 May 2023 Results Q1/23 Follow Fresenius Investor Relations & Sustainability on 17 May 2023 Annual General Meeting LinkedIn: 02 August 2023 Results Q2/23 02 November 2023 Results Q3/23 Please note that these dates could be subject to cha

  38. Slide 38: = FRESENIUS

    = FRESENIUS

Fresenius SE & Co. KGaA — Non-Deal Roadshow (May 2023) on 6ix